$CLNN Cashflow Statement | Understand Stock

$CLNN

$3.97 +$0.13 (3.39%) Close

$CLNN Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Non-cash lease expense
Commitment share expense
Issuance costs for common stock warrant liabilities
Loss on initial issuance of equity
Issuance of common stock as payment of outstanding indebtedness
Change in fair value of common stock warrant liabilities
Change in fair value of common stock warrant liability
Change in fair value of derivative liabilities
Change in fair value of Clene Nanomedicine contingent earn-out liability
Change in fair value of Initial Stockholders contingent earn-out liability
Stock-based compensation expense
Change in fair value of derivative
Gain on termination of lease
Loss on sale of marketable securities
Loss on extinguishment of notes payable
Notes Payable to Banks
Total loss on extinguishment of notes payable

Loss on extinguishment of convertibles notes payable
Loss on disposal of property and equipment
Accretion of debt discount
Change in fair value of notes payable
Non-cash interest expense
Non-cash interest income on marketable securities
Non-cash interest expense on notes payable

Changes in operating assets and liabilities:
Accounts receivable
Inventory
Prepaid expenses and other current assets
Accounts payable
Accrued liabilities
Income tax payable
Payable to related parties
Deferred revenue from related parties
Deferred income tax
Operating lease obligations
Net cash used in operating activities

Cash flows from investing activities:
Purchases of marketable securities
Proceeds from maturities of marketable securities
Proceeds from sales of marketable securities
Purchases of property and equipment
Net cash provided by (used in) investing activities
Cash flows from financing activities:
Proceeds from exercise of stock options
Proceeds from warrants exercised
Proceeds from issuance of common stock, net of offering costs
Proceeds from issuance of common stock, warrants, and pre-funded warrants, net of offering costs
Proceeds from the issuance of debt and derivative liabilities
Payments of notes payable
Proceeds from the private placement
Private Placement
Total proceeds from the private placement
Payment of deferred offering costs
Proceeds from the Reverse Recapitalization and from the private placement
Proceeds from issuance of Series D Preferred Stock, net of issuance costs
Proceeds from the issuance of convertible notes payable
Payments of notes payable modification fees
Payments of finance lease obligations
Proceeds from the issuance of notes payable
Payments of notes payable issuance costs
Net cash provided by (used in) financing activities
Net decrease in cash, cash equivalents and restricted cash
Cash and restricted cash - beginning of year
Cash and restricted cash - end of year
Cash, cash equivalents and restricted cash – beginning of period
Cash, cash equivalents and restricted cash – end of period

Effect of foreign exchange rate changes on cash and restricted cash
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:
Cash and cash equivalents
Restricted cash
Cash, cash equivalents and restricted cash
Supplemental disclosure of non-cash investing and financing activities:
Common stock warrant liability recorded upon debt modification
Stock issued
Payment of Outstanding Indebtedness
Payment of Bonus Liability
Supplemental cash flow information:
Cash paid for interest expense
Derivative liability recorded upon debt modification
Derivative liability recorded upon debt issuance
Common stock warrant liability recorded upon public stock offering
Lease liability arising from obtaining right-of-use assets, leasehold improvements, and lease incentives
Lease incentive realized
Lease liability settled through termination of lease
Issuance of derivative instrument related to convertible notes
Issuance of Series D Preferred Stock upon extinguishment of convertible promissory notes
Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes
Deferred transaction costs in accounts payable
Deferred transaction costs in accrued liabilities
Conversion of redeemable convertible preferred stock into common stock
Extinguishment of preferred stock warrant liability in connection with the conversion of redeemable convertible preferred stock
Issuance of common stock as payment of related offering costs
Clene Nanomedicine contingent earn-out recognized in connection with the Reverse Recapitalization
Initial Shareholders contingent earn-out recognized in connection with the Reverse Recapitalization
Reclassification of common stock warrant liability to permanent equity
Purchases of property and equipment in accounts payable
Common stock warrant liability recorded at issuance of notes payable

Comments